申请人:Wei T. Edward
公开号:US20050084447A1
公开(公告)日:2005-04-21
One embodiment of the invention is a composition that comprises a radioactive [
18
F], [
123
I], [
125
I], or [
131
I]—N-radiohaloaryl-alkylcarboxamide molecule. The composition binds to the transient receptor potential-M8 (TRP-M8) receptor of cells. The TRP-M8 receptor is selectively expressed in sensory neurons and in malignant tissues such as prostate cancer cells. The [
18
F], [
123
I], [
125
I], or [
131
I]—N-radiohaloaryl-alkylcarboxamide ligand may be used for radioreceptor binding studies, for diagnostic studies, and for radiotherapy of cancerous tissues. Affinity of the [
125
I] or [
131
I]—N-radiohaloaryl-alkylcarboxamide ligand for the TRP-M8 receptor confers selectivity and specificity in delivering lethal radiation to the diseased cells.
发明的一个实施例是一种包含放射性[18F]、[123I]、[125I]或[131I]—N-放射性卤芳基-烷基羧酰胺分子的组合物。该组合物结合到细胞的瞬时受体电位-M8 (TRP-M8) 受体上。TRP-M8 受体在感觉神经元和恶性组织(如前列腺癌细胞)中选择性表达。[18F]、[123I]、[125I]或[131I]—N-放射性卤芳基-烷基羧酰胺配体可用于放射受体结合研究、诊断研究以及癌细胞组织的放射治疗。[125I]或[131I]—N-放射性卤芳基-烷基羧酰胺配体对TRP-M8 受体的亲和力赋予了在将致命辐射传递给患病细胞时的选择性和特异性。